Q32 Bio announced positive topline results from the 36-week Part B of its SIGNAL-AA Phase 2a clinical trial for bempikibart, a drug targeting severe alopecia areata. The trial showed meaningful hair regrowth and a good safety profile. The company plans to start a registration-directed Phase 3 program in the first half of 2027, pending regulatory discussions. With $106.3 million cash plus $200 million raised in July 2026, Q32 Bio is financially positioned to advance its development program and explore broader applications of bempikibart and a related antibody, ADX-914-XL.
EverBank Financial Corp and WaFd, Inc. have agreed to merge, combining their banking operations to form a larger, more profitable institution. The merger will result in WaFd, Inc. being the surviving entity, renamed EverBank Financial Corp, and tradi...
Boyaa Interactive, a Hong Kong-listed gaming company, purchased an additional 115 Bitcoin, increasing its total holdings to approximately 4,316 BTC. This move places Boyaa as the 22nd largest public company Bitcoin holder worldwide. The company acqui...
Six Flags has partnered with FinTech company Upgrade to launch Flex Pay, a buy now, pay later (BNPL) option for purchasing season passes. Guests can buy passes online for $49 or more and pay in fixed monthly installments while enjoying immediate acce...
President Donald Trump declared that Canadian aircraft maker Bombardier should be banned from selling planes in the US unless they are manufactured domestically. Trump criticized Canada for unfair trade restrictions on American companies and highligh...
Xverse, a self-custodial Bitcoin wallet, has launched a pooled Bitcoin staking product allowing users to earn Bitcoin-denominated yields without giving up control of their coins. The staking uses sBTC on the Stacks network paired with STX tokens, kee...
